GGrantIndex
← Search

Flow Cytometry

$540,453P30FY2011CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Trial NCT07407920Trial NCT07349641Trial NCT06651580Trial NCT05681026Trial NCT05223036Trial NCT05078866Trial NCT05057312Trial NCT05054296Trial NCT05044546Trial NCT05023967Trial NCT05011045Trial NCT04875728Trial NCT04870645Trial NCT04810091Trial NCT04751422Trial NCT04740164Trial NCT04668300Trial NCT04615013Trial NCT04505267Trial NCT04484909Trial NCT04483349Trial NCT04481204Trial NCT04474301Trial NCT04458610Trial NCT04447222Trial NCT04435691Trial NCT04430725Trial NCT04407247Trial NCT04373720Trial NCT04317781Trial NCT04311723Trial NCT04310826Trial NCT04310397Trial NCT04265430Trial NCT04257045Trial NCT04256941Trial NCT04239989Trial NCT04239976Trial NCT04239157Trial NCT04236882Trial NCT04228042Trial NCT04220827Trial NCT04220775Trial NCT04220008Trial NCT04219969Trial NCT04219904Trial NCT04216732Trial NCT04216563Trial NCT04216524Trial NCT04216472Trial NCT04215029Trial NCT04200534Trial NCT04199026Trial NCT04196972Trial NCT04189783Trial NCT04189770Trial NCT04189757Trial NCT04188418Trial NCT04188405Trial NCT04186884Trial NCT04186832Trial NCT04185337Trial NCT04181463Trial NCT04171622Trial NCT04171219Trial NCT04171037Trial NCT04169763Trial NCT04169737Trial NCT04169542Trial NCT04160052Trial NCT04151082Trial NCT04150939Trial NCT04140487Trial NCT04135326Trial NCT04134208Trial NCT04132843Trial NCT04132505Trial NCT04132440Trial NCT04129138Trial NCT04128748Trial NCT04128501Trial NCT04127721Trial NCT04125914Trial NCT04119037Trial NCT04106843Trial NCT04106245Trial NCT04090619Trial NCT04090567Trial NCT04087057Trial NCT04083378Trial NCT04082572Trial NCT04074746Trial NCT04066894Trial NCT04062305Trial NCT04062266Trial NCT04058964Trial NCT04054245Trial NCT04054167Trial NCT04054154Trial NCT04053517

Abstract

The Flow Cytometry and Cellular Imaging Core Facility (FCCICF) provides cellular analysis to investigators with peer-reviewed grants. The FCCICF has two sites, on the north campus and on the recently-opened south campus. It occupies 1900 sq. ft. and is directed by Dr. Michael Andreeff. The FCCICF develops and provides techniques for single-cell analysis. Cell phenotyping, proliferation, signaling and apoptosis assays have been established and modified for multiparametric analysis. Immunophenotypic analysis was combined with assays of intracellular proteins related to apoptosis (Bcl-2, Bcl-XL, BAG-1, p53, Rb, caspase activation, mitochondria! membrane potential and Fas), cell signaling (MARK), proliferation (Ki67, cyclins, BrDU, PCNA, DNA) and cell division history (CFSE). Quantitation of cellular antigens allows determination of the antibodybinding capacity per cell. Rare events and progenitor/stem cell subpopulations can be detected and isolated by three-laser excitation/eight-parameter fluorescence-activated cell sorting (FACS) for subsequent analysis by molecular cytogenetic and other molecular techniques including quantitation of intracellular PKCoc, Bax, Bcl-2, ERK, pERK, XIAP by laser scanning cytometry. FISH has been combined with apoptosis assays to discriminate apoptosis in normal and malignant cells. The number, phenotype and proliferation of minimal residual disease cells can be determined at levels of one malignant in 30,000 normal cells. Methods for detection of transgene expression in cells are in place using p-galactosidase (p-gal), nerve growth factor receptor (NGF-R), and green fluorescent protein (EGFP). Acquisition of 3 new FACS Aria cell sorters and a four-laser flow cytometer (B&D LSRII) has upgraded the facility to provide state-of-the-art isolation and analysis. Laser confocal microscopy has been used extensively and was upgraded by acquisition of an Olympus FV-500 multi-user instrument and a DSU spinning disc confocal system. High-impact studies in cancer prevention, growth factor signaling in breast cancer, apoptosis regulation in leukemias and multistep tumorigenesis all utilized confocal microscopy. The FCCICF now utilizes 17 major instrument systems. The Core supports numerous R01, P01, R21, and SPORE grants. Since the previous review, the number of users has increased 145% (169 investigators with peer-reviewed grants from 19 different programs). 67% of users have peer-reviewed funding. During the previous funding period, 11,668 hours of service was provided. Use has tripled to greater than 7,000 hours estimated for 2007. Future plans are focused on the continued development and application of cutting-edge technologies in cell analysis.

View original record on NIH RePORTER →